# **CRDP**

## PROVIDER BULLETIN

June 3, 2005

#### CRDP FORMULARY CHANGES

**Effective May 24, 2005,** Fosrenol® (lanthanum carbonate) and Sensipar ® (cinacalcet HCl) are being included in the CRDP formulary for <u>consideration of reimbursement by CRDP through the medical exception process.</u>

Claims for these agents will deny with a NCPDP Error of "70"-- NDC not on file; accompanied by the response code "CH" –Call Help Desk.

#### **Fosrenol®**

Medical exceptions for Fosrenol® will only be approved following receipt of documentation from the prescriber substantiating a CaPO4 level of 70 or greater.

Approved Fosrenol® medical exceptions will be for a maximum of 3000mg per day.

**Note**: Both Fosrenol® and Renagel® are phosphate binding agents. Approved Fosrenol® claims received for CRDP patients currently receiving Renagel® **will deny** for duplicate therapy.

### Sensipar® (cinacalcet HCI)

Medical exceptions for Sensipar® will only be approved following receipt of documentation from the prescriber substantiating that the CRDP cardholder has a iPTH of 400 or greater.

Approved medical exceptions:

- will be initiated at a maximum dose of 30mg/day.
- Dosing levels *may* be increased if prescriber documentation demonstrates improvement in the cardholder's iPTH level.

**Important:** Sensipar® patients also receiving Renagel® who develop calcium levels less than or equal to 8 will have future claims for Renagel® denied.

Questions may be directed to Provider Services at: 1-800-835-4080.